IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CATTANEO, DARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.476
AS - Asia 5.449
EU - Europa 5.098
Continente sconosciuto - Info sul continente non disponibili 725
SA - Sud America 502
AF - Africa 193
OC - Oceania 27
Totale 18.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.160
SG - Singapore 1.652
GB - Regno Unito 1.551
CN - Cina 1.522
IT - Italia 1.211
VN - Vietnam 535
BD - Bangladesh 525
DE - Germania 465
RU - Federazione Russa 378
SE - Svezia 375
BR - Brasile 370
HK - Hong Kong 366
FR - Francia 255
IN - India 239
NL - Olanda 222
CA - Canada 221
FI - Finlandia 142
IE - Irlanda 129
TR - Turchia 119
KR - Corea 97
JP - Giappone 80
ES - Italia 71
CI - Costa d'Avorio 67
ID - Indonesia 66
BE - Belgio 52
UA - Ucraina 49
ZA - Sudafrica 48
MX - Messico 36
AR - Argentina 35
DK - Danimarca 30
PL - Polonia 28
CH - Svizzera 25
AU - Australia 24
IQ - Iraq 22
IR - Iran 22
PK - Pakistan 22
UZ - Uzbekistan 22
CL - Cile 20
EU - Europa 20
SA - Arabia Saudita 19
TW - Taiwan 19
EC - Ecuador 18
GR - Grecia 18
PH - Filippine 18
AT - Austria 17
CO - Colombia 17
TH - Thailandia 14
VE - Venezuela 14
CZ - Repubblica Ceca 13
NP - Nepal 13
RO - Romania 13
AE - Emirati Arabi Uniti 12
PT - Portogallo 12
EG - Egitto 11
JM - Giamaica 11
KE - Kenya 10
PY - Paraguay 10
JO - Giordania 9
PE - Perù 9
HN - Honduras 8
MA - Marocco 8
MY - Malesia 8
NO - Norvegia 8
TN - Tunisia 8
IL - Israele 7
PA - Panama 7
DO - Repubblica Dominicana 6
GT - Guatemala 6
PR - Porto Rico 6
UY - Uruguay 6
BW - Botswana 5
CR - Costa Rica 5
ET - Etiopia 5
MZ - Mozambico 5
NG - Nigeria 5
AL - Albania 4
AZ - Azerbaigian 4
BB - Barbados 4
BG - Bulgaria 4
BY - Bielorussia 4
DZ - Algeria 4
HR - Croazia 4
LB - Libano 4
MM - Myanmar 4
QA - Qatar 4
GH - Ghana 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LK - Sri Lanka 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SC - Seychelles 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
BF - Burkina Faso 2
BH - Bahrain 2
BO - Bolivia 2
HU - Ungheria 2
KH - Cambogia 2
LV - Lettonia 2
Totale 17.732
Salva come PNG Salva come JPEG
Città #
Southend 1.380
Singapore 1.007
Ashburn 696
Chandler 474
Milan 440
Hong Kong 320
Dallas 317
San Jose 310
Beijing 247
Santa Clara 214
Wilmington 202
Seattle 189
Fairfield 186
Council Bluffs 184
Ann Arbor 183
Los Angeles 175
Ho Chi Minh City 170
Princeton 167
New York 163
Boardman 131
Dublin 127
Hanoi 120
Dearborn 100
Houston 97
Toronto 97
Lauterbourg 94
Munich 86
Woodbridge 84
The Dalles 82
Frankfurt am Main 79
Bengaluru 76
Guangzhou 75
Nanjing 74
Buffalo 71
Rome 70
Abidjan 67
Des Moines 67
Phoenix 64
Cambridge 63
Istanbul 62
Helsinki 59
Moscow 59
Redwood City 55
Hefei 54
Columbus 44
Da Nang 44
Shanghai 44
Shenyang 44
Tokyo 43
Brussels 41
Cangzhou 35
Jakarta 35
São Paulo 33
Berlin 30
Zhengzhou 30
Atlanta 28
Hanover 28
Ottawa 27
Redmond 27
Turin 27
Jinan 26
Montreal 26
Naples 26
Seoul 26
Changsha 25
Mountain View 25
Tianjin 24
Amsterdam 23
Brooklyn 22
Chennai 22
Chicago 22
Haiphong 22
Shenzhen 22
Turku 22
Kiez 21
Washington 21
Falls Church 20
San Diego 20
Denver 19
Hebei 19
Johannesburg 18
Orem 18
Nanchang 17
Boise 16
Bologna 16
London 16
Paris 16
Fuzhou 15
Nuremberg 15
Rio de Janeiro 15
Warsaw 15
Bari 14
Dhaka 14
Mumbai 14
Tashkent 14
Haikou 13
Madrid 13
Catania 12
Chengdu 12
Grafing 12
Totale 10.345
Salva come PNG Salva come JPEG
Nome #
Fosfomycin therapeutic drug monitoring in real-life: development and validation of a LC-MS/MS method on plasma samples 523
Antihypertensive drugs and brain function: mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects 432
Impact of Therapeutic Drug Monitoring of Antiretroviral Drugs in Routine Clinical Management of People Living with HIV: A Narrative Review 429
Comparison of the pharmacokinetics of raltegravir given at 2 doses of 400 mg by swallowing versus one dose of 800 mg by chewing in healthy volunteers : a randomized, open-label, 2-period, single-dose, crossover phase 1 study 407
Clinical features and outcomes of HIV patients with coronavirus disease 2019 367
When food can make the difference : The case of elvitegravir-based co-formulation 359
Inflammation and neurological adverse drugs reactions : a case of long lasting impaired consciousness after oxatomide administration in a patient with gastroenteritis 352
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients : is it time to revise atazanavir dosages? 348
Can We Rely on AGNP Therapeutic Targets also for LAI Antipsychotics? 311
Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype 310
Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies : evidence from Phase I studies in healthy volunteers 295
Effect of N-Desalkylquetiapine/Quetiapine Plasma Level Ratio on Anxiety and Depression in Bipolar Disorder: A Prospective Observational Study 295
Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine 287
Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure 282
Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients : an observational study in real-life settings 264
Risks of potential drug–drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience 251
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting 246
Effetto "contesto" nel trattamento farmacologico infusivo della depressione resistente: dalla teoria a uno studio sperimentale 241
Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study 229
Serotonin reuptake inhibitors in pregnancy : can genes help us in predicting neonatal adverse outcome? 227
Application of Quality by Design Approach to Bioanalysis: Development of a Method for Elvitegravir Quantification in Human Plasma 226
Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies : evidence from a safety study with pilot efficacy measures in adult dystrophic patients 225
Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations : Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy 225
Pharmacovigilance knowledge in family paediatricians. A survey study in Italy 222
Neonatal Outcomes of Newborns Exposed to SSRI during Pregancy: a Pharmacokinetic and Pharmacogenetic Analysis 214
In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5 214
Non-operative management of uncomplicated appendicitis in children, why not? A meta-analysis of randomized controlled trials 213
Are non-serious adverse reactions to psychiatric drugs really non-serious ? 213
Determinants of bone diseases in tenofovir-treated HIV patients 209
Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients 207
Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients 206
Persistence in Therapy With Risperidone and Aripiprazole in Pediatric Outpatients : A 2-Year Naturalistic Comparison 198
Management of Polypharmacy and Potential Drug–Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic 197
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient 196
Selective serotonin reuptake inhibitors’ passage into human milk of lactating women 196
Development and validation of a chromatographic ultraviolet method for the simultaneous quantification of dolutegravir and rilpivirine in human plasma 196
Acute generalized exanthematous pustulosis induced by paroxetine in an adolescent girl 195
Comparison of the ARK Immunoassay With High-Performance Liquid Chromatography With Ultraviolet Detection for Therapeutic Drug Monitoring of Linezolid 195
Prolonged inductive effect of rifampicin on linezolid exposure 194
Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections 193
Perceptions and patterns of use of generic drugs among Italian family pediatricians : first round results of a web survey 190
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial 186
Second generation antipsychotics in 'real-life' paediatric patients : adverse drug reactions and clinical outcomes of drug switch 184
Tenofovir plasma trough concentrations in people with HIV treated with doravirine versus other antiretroviral regimens 184
Limited Sampling Strategies for the Estimation of Raltegravir Daily Exposure in HIV-Infected Patients 182
ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor? 182
Comparison of the QMS® analyzer with HPLC-UV for the quantification of lamotrigine concentrations in human plasma samples 182
Consumption of antibiotics at an Italian university hospital during the early months of the COVID-19 pandemic: Were all antibiotic prescriptions appropriate? 182
Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes 181
Is it time to revise antiretrovirals dosing? : a pharmacokinetic viewpoint 181
Supra-therapeutic Linezolid Trough Concentrations in Elderly Patients : a Call for Action? 179
Levofloxacin-induced seizures in a patient without predisposing risk factors : the impact of pharmacogenetics 176
Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience 176
High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis 174
Relapse of Kaposi's Sarcoma and HHV-8 viremia in an HIV-infected patient switching from protease inhibitor to integrase inhibitor-based antiretroviral therapy 171
Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count 170
Lights and shadows of the actual European guidelines on bioanalytical method validation : the case of raltegravir 170
Preventing COVID-19 in assisted living facilities: An impossible task pending vaccination roll out 169
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration 167
Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma 166
Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans 165
Potential benefits and limits of psychopharmacological therapies in pervasive developmental disorders 157
Proactive therapeutic monitoring of dalbavancin concentrations in the long-term management of chronic osteoarticular/periprosthetic joint infections 156
Management of Polypharmacy and Potential Drug-Drug Interactions in Patients with Pulmonary Aspergillosis: A 2-Year Study of a Multidisciplinary Outpatient Clinic 153
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment 152
The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression : a case report 151
Combining clozapine with cariprazine: Two case reports highlighting potential drug-drug interaction 149
Linezolid-related haematological toxicity in a peritoneal dialysis patient: the role of therapeutic drug monitoring 146
Different effects of glucocorticoids on darunavir plasma concentrations 145
Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots 142
Management of diabetes mellitus in people living with HIV: A single-center experience 141
Comparison of the in vivo pharmacokinetics and in vitro dissolution of branded versus generic efavirenz formulation in HIV-infected patients 140
Mismanagement of SARS-CoV-2 Infection Pre Hospitalisation during the Omicron Era: Antibiotics and Steroids Instead of Early Antivirals 140
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir 139
Orlistat: weight lost at cost of HIV rebound 138
Dolutegravir and metformin : a clinically relevant or just a pharmacokinetic interaction? 138
Is it time to revise linezolid doses in peritoneal dialysis patients? A case series 137
Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy? 128
Therapeutic drug management of linezolid : a missed opportunity for clinicians? 127
Pharmacokinetics of oral anticoagulants in patients with atrial fibrillation and extreme obesity 127
Pharmacogenetics-based optimisation of atazanavir treatment : potential role of new genetic predictors 124
Appropriateness of loading dose and TDM in patients treated with teicoplanin: a single-centre observational retrospective cohort study comparing single-daily and thrice-weekly regimens 118
Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring 117
Effect of body mass index on the timing of therapeutic drug monitoring—guided dalbavancin dosing in patients with osteoarticular infections 116
Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients 107
Is chewed raltegravir an option to care for HIV-infected patients with active tuberculosis? 105
Drug-induced liver steatosis in patients with HIV infection 99
Tenofovir plasma concentrations in post-menopausal versus pre-menopausal HIV-infected women 94
Polypharmacy and Aging in People Living with HIV: 6 Years of Experience in a Multidisciplinary Outpatient Clinic 92
Severe hyperbilirubinemia in an HIV-HCV coinfected patient starting the 3D regimen that resolved after TDM-guided atazanavir dose reduction 86
Does lopinavir really inhibit SARS-CoV-2? 86
Optimizing antibiotic therapy for intravenous drug users: a narrative review unraveling pharmacokinetics/pharmacodynamics challenges 80
How relevant is the interaction between dolutegravir and metformin in real life? 80
Pharmacokinetic profile of dolutegravir after transjugular intrahepatic portosystemic shunt placement 80
Deltoid Administration of LAI-ART: Pharmacokinetic Implications When the Gluteal Site Is Not Feasible 23
Seminal plasma concentrations of long-acting cabotegravir in men receiving HIV pre-exposure prophylaxis 17
Management of polypharmacy and potential drug-drug interactions in people with HIV and cancer: insights from a 4-year multidisciplinary clinic experience 15
Pharmacokinetic evaluation of doravirine and dolutegravir during paclitaxel-based chemotherapy: a case report in an HIV-positive woman with metastatic pancreatic cancer 13
null 6
Totale 18.470
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.802
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.802
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.032 0 39 46 58 65 73 81 57 207 115 46 245
2022/20231.480 179 193 164 143 153 249 33 77 174 17 60 38
2023/20241.107 48 84 65 81 233 144 47 59 51 49 132 114
2024/20252.830 103 236 50 299 260 134 77 237 186 308 271 669
2025/20266.373 603 406 617 553 622 370 892 204 542 383 687 494
2026/2027882 434 448 0 0 0 0 0 0 0 0 0 0
Totale 18.470